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Objective: To develop a short and easy to use questionnaire 
to measure use and usability of custom-made orthopaedic 
shoes, and to investigate its reproducibility.
Design: Development of the questionnaire (Monitor Ortho-
paedic Shoes) was based on a literature search, expert in-
terviews, 2 expert meetings, and exploration and testing of 
reproducibility. The questionnaire comprises 2 parts: a pre 
part, measuring expectations; and a post part, measuring 
experiences.
Patients: The pre part of the final version was completed 
twice by 37 first-time users before delivery of their orthopae-
dic shoes. The post part of the final version was completed 
twice by 39 first-time users who had worn their orthopaedic 
shoes for 2–4 months.
Results: High reproducibility scores (Cohen’s kappa > 0.60 
or intra class correlation > 0.70) were found in all but one 
question of both parts of the final version of the Monitor Or-
thopaedic Shoes questionnaire. The smallest real difference 
on a visual analogue scale (100 mm) ranged from 21 to 50 
mm. It took patients approximately 15 min to complete one 
part.
Conclusion: Monitor Orthopaedic Shoes is a practical and 
reproducible questionnaire that can measure relevant as-
pects of use and usability of orthopaedic shoes from a pa-
tient’s perspective.
Key words: orthopaedic shoes, usability, questionnaire, patient 
satisfaction.
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INTRODUCTION
Custom-made orthopaedic shoes (OS) can be used to diminish 
or prevent serious foot and/or ankle problems for a wide-range 
of patient groups (e.g. patients with diabetes, rheumatoid 
arthritis, degenerative foot disorders, muscle diseases) (1–3). 
OS are frequently prescribed in the Netherlands, with almost 
50,000 pairs provided in 2006 (4). The total cost of OS in that 
year was almost 60 million Euros (4). In England and Wales, 
approximately 200,000 persons were provided with OS by the 
National Health Service (NHS) in 2000, with an expenditure 
of almost 40 million pounds sterling (5). 
The non-use of OS is a well-known problem. Non-use 
rates vary, ranging from 20% to 25% for first-time users (2, 
6, 7), and from 4% to 19% when experienced users who were 
provided with a subsequent pair of OS were also taken into 
account (8–11). Non-use is influenced by the usability of 
OS. Usability is “the extent to which a product can be used 
by specified users to achieve specified goals with effective-
ness, efficiency, and satisfaction, in a specified context of 
use” (International Organization for Standardization (ISO), 
9241-11). Within the domains of usability stated, effective-
ness, efficiency and satisfaction, the following aspects are 
associated with non-use of OS: benefits of OS with regard to 
walking capacities, wound healing, pain, etc. (domain effec-
tiveness); comfort and ease of use, and the efficiency of the 
delivery process of OS (domain efficiency); communication 
with prescribing specialists, and cosmetic appearance (domain 
satisfaction) (2, 6–21). However, in a systematic review it was 
concluded that none of the randomized clinical trials focused 
on all these domains of usability (22). Subsequently, Jannink 
et al. (2) focused on all domains of usability, however, only 
in patients with degenerative disorders of the foot. Therefore, 
further insight into the usability of OS in a wide range of 
patient groups is required.
Of the instruments that are available to gain insight into 
aspects of use and usability of OS, only the Questionnaire for 
Usability Evaluation (QUE) quantifies aspects of all domains 
of usability as defined by the ISO (22, 23). However, the 
QUE was developed specifically for patients with degenera-
tive disorders of the foot. Even more importantly, the QUE is 
a lengthy and time-consuming questionnaire (it takes about 
30 min to complete one questionnaire (pre or post part)), which 
limits its practical application. Therefore, the aim of the present 
study was to develop a short and easy to use questionnaire that 
could measure the most relevant aspects of use and usability 
of OS from a patient’s perspective, in a wide-range of patient 
groups. In addition, reproducibility of the questionnaire was 
studied. 
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METHODS
The development of the questionnaire, Monitor Orthopaedic Shoes 
(MOS), comprised 7 phases: 1) literature search and expert interviews; 
2) development of the first (pilot) version (termed MOSv1); 3) expert 
meetings to discuss MOSv1; 4) development of the second version 
(MOSv2); 5) exploration of the reproducibility of MOSv2; 6) develop-
ment of the final version (MOSfv); and 7) testing MOSfv   for reproduc-
ibility. The procedures and patient inclusion criteria were the same 
for exploration (phase 5) and testing (phase 7) of reproducibility, and 
will therefore be described in the paragraph concerning phase 5. The 
methodology of the development of MOS is shown in Fig. 1. 
MOS was developed specifically for first-time users of OS, because 
there is a large difference between first-time and experienced users, 
especially with regard to their expectations (8). MOS was developed 
primarily in Dutch, and reproducibility was defined in the Dutch 
language.
Phase 1 – Literature search and expert interviews
Articles were sought in MEDLINE (1989–2008) and EMBASE 
(1989–2008), using combinations of the following keywords: orthopae-
dic, therapeutic, surgical, prescribed, shoe, foot, patient satisfaction, 
usability, non-use, diabetes mellitus, rheumatic diseases, foot deformi-
ties, foot-diseases. The combination of keywords used in MEDLINE is 
shown in Appendix I. This combination was adapted to suit EMBASE. 
The initial selection of articles was based on the title and the content 
of the abstract. The reference lists of relevant publications found were 
checked carefully. A total of 17 articles concerning use and usability 
of OS were identified (2, 6–21).
To obtain additional information from clinical practice, semi-
structured expert interviews were held with specialists in rehabilitation 
medicine (n = 3), certified orthopaedic shoe technicians (n = 3) and an 
experienced user of OS (n = 1). These experts were interviewed about 
the importance of the different aspects of usability of OS, different 
goals of OS, the relevance of different activities of the user, and the 
expectations of users.
Phase 2 – Development of MOSv1
Based on the literature search and the expert interviews, the most 
relevant aspects of use and usability of OS, divided into the domains 
of usability, were determined and operationalized into the questions 
of MOSv1. MOSv1 comprised 2 parts, a pre part (MOSprev1) and a 
post part (MOSpostv1). MOSprev1 is completed by patients prior to 
receiving their first pair of OS. MOSprev1 was designed to measure the 
expectations of the patient and the current status of several outcome 
variables. MOSpostv1 was designed as a follow-up to measure experi-
ences with use and usability of patients’ OS and the change in outcome 
variables. MOSpostv1 is completed after patients have worn their OS 
for 2–4 months, with no insight into the answers of MOSprev1. The 
interviewed experts indicated that a period of 2 months is necessary 
to become accustomed to OS and that after 4 months problems with 
wearing-out of OS may have already developed. 
MOSv1 comprised questions in different forms: multiple choice, 
visual analogue scale (VAS), open, and photo-based questions. 
Phase 3 – Expert meetings
Content validity was taken into account during all phases of the de-
velopment of MOS. It was not possible to determine criterion validity, 
because no similar measuring instrument to MOS exists. The QUE, 
which is most closely related, was developed only for patients with 
degenerative disorders of the foot, whereas MOS was developed for 
a wide-range of patient groups.
In order to ensure good content validity, 2 meetings were organized 
with experts who did not take part in a previous phase of this study. 
One meeting was held with specialists in rehabilitation medicine (n = 2) 
and certified orthopaedic shoe technicians (n = 4), and a second with 
experienced users of OS (n = 5). In these meetings, all experts were 
asked to comment on all aspects of MOSv1. A general discussion was 
held during both meetings regarding the relevance of the questions, 
and any important aspects missing about the use and usability of OS. 
Following this, a specific discussion was held regarding the clarity 
and practical application of each question in MOSv1. 
Phase 4 – Development of MOSv2 
Based on the recommendations and suggestions made during the expert 
meetings, MOSv2 was developed. MOSv2 was sent to the participants 
of both expert meetings again for final comment. This did not result 
in any changes. 
As MOSv1, MOSv2 comprised 2 parts: a pre part, measuring ex-
pectations and the current situation (MOSprev2), and a post part, 
measuring experiences and changes (MOSpostv2). MOSv2 comprised 
questions in different forms: multiple choice, VAS, open, and photo-
based questions. The expert meetings and pilot-testing indicated that 
patients understood the direction of the choices and how to answer 
the questions.
Phase 5 – Exploration of reproducibility of MOSv2
Patients. Inclusion criteria for patients were: (i) first-time user of OS; 
(ii) 16 years of age or older; (iii) able to read Dutch; and (iv) able 
to complete the questionnaire without help related to cognitive or 
physical impairments. 
Study design. Although MOSv2 comprised 2 related parts, MOSprev2 
and MOSpostv2, for practical reasons reproducibility was explored in 
2 separate groups in a within-group design. Patients were recruited 
from 2 participating orthopaedic shoe companies (OIM Orthopedie, 
Haren, The Netherlands and Roessingh Revalidatie Techniek (RRT), 
Enschede, The Netherlands). For MOSprev2, patients meeting the 
inclusion criteria were recruited by the orthopaedic shoe technician 
after their visit for foot measurements for a first pair of OS, whereas 
for MOSpostv2 patients were telephoned by the orthopaedic shoe 
technician if they had worn their first pair of OS for 2–4 months. After 
patients gave informed consent, MOSv2 was sent to them by post. Once 
MOSv2 was completed for the first time and received by the researchers, 
Fig. 1. Methodology of the development of the Monitor Orthopaedic 
Shoes (MOS) questionnaire. OS: orthopaedic shoes.
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MOSv2 was again sent to patients by post. Because of privacy matters, 
researchers had no insight into the personal characteristics of patients 
who did not give informed consent. The procedures of this study were 
approved by the medical ethics committee of the University Medical 
Center Groningen.
Data analysis. Reproducibility was analysed using SPSS for Windows, 
version 16.0 (SPSS Inc. Chicago, IL, USA). The reproducibility of the 
multiple choice questions was analysed using Cohen’s kappa. A kappa 
value of less than 0.40 indicates poor to fair agreement, 0.41–0.60 
moderate agreement, 0.61–0.80 substantial agreement, and 0.81–1.00 
almost perfect agreement (24). The reproducibility of the VAS ques-
tions was analysed using an intra-class correlation (ICC), absolute 
agreement, 2-way random model for single measures. This model 
measures the degree of absolute agreement among the scores on the 
first and the second completed questionnaire (25). In general, values 
over 0.70 are considered as high agreement (24). The 95% confidence 
interval of the ICC was also calculated. The open and photo-based 
questions were not included in the reproducibility analysis.
In addition, the standard error of measurement (SEM) and the small-
est real difference (SRD) of the VAS questions were also calculated. 
The SEM is the square-root of the within-subject variance (26), the 
SRD is 1.96*√2*SEM (27). Both are expressed in the same dimen-
sion as the measurement. The SEM provides an interpretation of the 
magnitude of within-subject variability, whereas the SRD indicates 
the point where the difference between 2 consecutive measurements 
within a subject can be interpreted as a real difference (26, 27).
Results of the exploration of reproducibility. MOSprev2 was completed 
twice by 20 out of 23 patients; MOSpostv2 was completed twice by 
9 out of 13 patients. The interval between completing MOSv2 for the 
first and the second time varied between 1 and 3 weeks. This is a 
usual test-retest interval (26). It was not expected that any clinically 
relevant changes in patients’ health status occurred in this period. High 
reproducibility scores (> 0.70) were found in 47 out of 62 questions. 
The SRD showed a range of 18–50 mm. Because this was only an 
exploration of the reproducibility in a small group of patients, results 
will not be presented in detail.
Additional questions were answered by all patients regarding: the 
inclusion of all relevant aspects of use and usability of OS; whether 
each question was clear to them; and different aspects of clarity and 
practical application of MOSv2 (for example: ”Did you have enough 
space for your answers?”; ”Is the font clear and readable?”; ”What do 
you think of the length of MOS?”). Six questions (3 in MOSprev2 and 
3 in MOSpostv2) were not clear for the patients. Patients were satisfied 
with the aspects of clarity and practical usefulness. 
Phase 6 – Development of MOSfv
Based on the results of this exploration, MOSfv was developed. 
Compared with MOSv2, 8 questions were deleted (5 in MOSprev2 and 
3 in MOSpostv2), 11 questions were adjusted (7 in MOSprev2 and 4 
in MOSpostv2), and 4 questions were added (2 in both MOSprefv and 
MOSpostfv). It was ensured that the most relevant aspects of use and 
usability were still covered in MOSfv.
As with the previous versions, MOSfv comprised 2 parts: MOS-
prefv, measuring expectations and the current situation by means of 
15 multiple choice questions and 12 VAS questions, and MOSpostfv, 
measuring experiences and changes by means of 11 multiple choice 
questions and 19 VAS questions. Both parts also contain open (5 and 7, 
respectively) and photo-based (2 in both) questions. MOSfv was sent to 
the participants of both expert meetings again for comments. This did 
not result in any changes, and experts indicated that the most relevant 
aspects of use and usability were included in MOSfv.
Phase 7 – Testing MOSfv for reproducibility
The same inclusion criteria, procedures, and data analysis as in phase 
5 were applied, apart from 2 differences with regard to the recruit-
ment of patients. Patients were recruited from OIM Orthopedie and 
Penders Voetzorg (Heythuysen, The Netherlands), instead of OIM 
Orthopedie and RRT, because Penders Voetzorg is a larger company 
with more patients. Furthermore, the same method of administration 
was of application for MOSprefv and MOSpostfv: at the same time, all 
patients from the 2 participating orthopaedic shoe companies meet-
ing the inclusion criteria were contacted by post by the orthopaedic 
shoe company. For MOSprefv, a mailing was sent to patients who had 
visited the orthopaedic shoe company for foot measurements for a 
first pair of OS in the last 2 months; for MOSpostfv, a mailing was 
sent to patients who had worn their first pair of OS for 2–4 months. 
The mailing contained an information letter and an informed consent 
form, the letter could be returned to the researchers by pre-stamped 
envelope. After receiving a consent form, MOSfv was sent to patients 
by post. Once MOSfv was completed for the first time and received by 
the researchers, MOSfv was again sent to patients by post.
MOSprefv was sent to 58 patients. 37 patients completed MOSprefv 
twice; 3 patients completed MOSprefv only once. MOSpostfv was sent 
to 49 patients. 39 patients completed MOSpostfv twice; 2 patients 
completed MOSpostfv only once. The interval between completing 
MOSfv for the first and the second time varied between 1 and 3 weeks. 
This is a usual test-retest interval (26). It was not expected that any 
clinically relevant changes in patients’ health status took place in this 
period. Patient characteristics are summarized in Table I. There were 
no major demographic differences between the groups.
RESULTS
Tables II and III list the results with respect to the reproduc-
ibility analysis, for MOSprefv and MOSpostfv, respectively. 
Cohen’s kappa for 13 questions was between 0.61 and 0.80, 
indicating substantial agreement. Cohen’s kappa for 8 ques-
tions was between 0.81 and 1.00, indicating almost perfect 
agreement. Cohen’s kappa of one question (regarding the 
patient’s expectation of other people’s opinion of the cosmetic 
appearance) was 0.47, which indicates moderate agreement. 
Detailed analysis of this question revealed that most variation 
was between the response possibilities “neutral” and “beauti-
ful” or “neutral” and “I do not know”. The ICC of all questions 
was above 0.70, which indicates high agreement. The SRD was 
in the range 21–50 mm. It took patients approximately 15 min 
to complete either the pre or the post part.
Table I. Characteristics of patients participating in the reproducibility 
study of the final version of the Monitor Orthopaedic Shoes (MOSfv) 
questionnaire
Characteristics MOSprefv (n = 37) MOSpostfv (n = 39)
Age, years, mean (SD) 66 (13) 67 (13)
Gender, female, n (%) 26 (70) 22 (56)
Disorder, n (%)*
Diabetes mellitus 9 (24) 13 (33)
Rheumatoid arthritis 10 (27) 7 (18)
Foot disorder† 22 (60) 29 (74)
Muscle disease 4 (11) 2 (5)
Other disease 10 (27) 12 (31)
*More than one disorder was possible; disorders were indicated by 
patients themselves. 
†Foot disorder was unspecified.
SD: standard deviation.
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DISCUSSION
The result of this study is a practical and reproducible question-
naire that can measure the most relevant aspects of use and 
usability of OS from a patient’s perspective, for a wide-range 
of patient groups. This questionnaire, MOS, can be applied 
at 2 levels: (i) to measure expectations (prior to prescription) 
and experiences with use and usability of OS in a group of 
patients; and (ii) to identify problems with OS on an individual 
level, prior to provision or after experience with OS. Insight 
into the use and usability of OS on both levels may lead to 
clearer identification of problems relating to the usability of 
OS, an increase in patient satisfaction, and an increased rate 
of use of OS.
It can be concluded that MOS is a reproducible question-
naire, because high agreement was found in all but one question 
of the final version. This one question explored the patient’s 
expectation of other people’s opinion of the cosmetic appear-
ance of their OS. It was apparent that patients’ concern for other 
people’s opinion 3 months before actual delivery of their OS 
is subject to much variation. As the detailed analysis showed, 
answers in the categories “neutral”, “beautiful”, or “I do not 
know” varied the most, thus these answers should be treated 
with care. It may be even better to not interpret this question 
at all. In contrast, the same question in the experienced part 
of MOS resulted in “almost perfect agreement”.
Relatively large SRD values were found, ranging from 21% 
to 50% of the VAS. When a part of MOS is completed twice by 
the same patient (e.g. by administering MOSpost after 3 and 
after 12 months of using OS), differences between consecutive 
scores should be large (greater than 21–50%) before they can 
be interpreted as a real difference. However, most scores were 
found near either one of the extreme end-points (e.g. patients 
either have a lot of pain or almost no pain; shoes fit either very 
badly or very well; etc.). It can be expected that a clinically 
relevant change will correspond with a shift from one extreme 
end-point to the other. The resulting large difference between 
the 2 scores will then likely be larger than the SRDs found. 
Table II. Results of the reproducibility analysis of the pre part of the final version of the Monitor Orthopaedic Shoes (MOSprefv) questionnaire 
(n = 37)
Domain n Cohen’s kappa n
ICC (CI) SRD, mm
Smallest Largest Smallest Largest
Use 1 0.66
Effectiveness
Walking capacity 3 0.72–0.76
Wounds 2 0.88–1.0
Pain 4 0.76 (0.56–0.87) 0.86 (0.74–0.93) 29 50
Sprains 2 0.76 (0.42–0.92) 0.93 (0.87–0.97) 25 31
Efficiency
Comfort in use 1 0.76 (0.57–0.87) 27
Satisfaction
Communication 4 0.72–0.80 2 0.84 (0.71–0.91) 0.84 (0.68–0.92) 26 27
Cosmetic appearance 2 0.47–1.0 1 0.72 (0.50–0.85) 42
Acceptability 2 0.84 (0.70–0.92) 0.85 (0.71–0.92) 21 31
Note: Three questions concerning demographic information are not shown.
n: number of questions, the range of the Cohen’s kappa is shown; ICC: Intra Class Correlation; CI: confidence interval; the smallest and largest ICC 
with corresponding CI are shown; SRD: smallest real difference; the smallest and largest SRD are shown.
Table III. Results of the reproducibility analysis of the post part of the final version of the Monitor Orthopaedic Shoes (MOSpostfv) questionnaire 
(n = 39)
Domain n Cohen’s kappa n
ICC (CI) SRD, mm
Smallest Largest Smallest Largest
Use 5 0.75–0.90 1 0.92 (0.85–0.96)
Effectiveness
   Walking capacity 2 0.78–0.89
   Wounds 2 0.93–1.0
   Pain 4 0.78 (0.52–0.91) 0.95 (0.89–0.98) 23 48
   Sprains 2 0.84 (0.62–0.94) 0.93 (0.85–0.96) 22 27
Efficiency
   Comfort in use 7 0.71 (0.50–0.85) 0.91 (0.82–0.95) 33 49
Satisfaction
   Communication 2 0.76 (0.55–0.88) 0.81 (0.66–0.90) 37 41
   Cosmetic appearance 1 0.82 1 0.86 (0.75–0.93) 36
   Acceptability 2 0.72 (0.52–0.85) 0.73 (0.51–0.86) 41 42
Note: One question concerning demographic information is not shown.
n: number of questions, the range of the Cohen’s kappa is shown; ICC: intra class correlation; CI: confidence interval; the smallest and largest ICC 
with corresponding CI are shown; SRD: smallest real difference; the smallest and largest SRD are shown.
J Rehabil Med 41
917Questionnaire for use and usability of orthopaedic shoes
Consequently, the large SRDs do not present a problem in the 
application of MOS.
Validity is regarded as the most fundamental consideration 
in developing and evaluating a measuring instrument (28). 
Various categories of validity have been described in the lit-
erature. Of these, construct validity is the overarching category 
that can be addressed in 2 different ways, by criterion and 
content validity (26, 29). Criterion validity is not relevant in 
this study, as no similar measuring instrument exists that can 
be used as a criterion. Emphasis has therefore been placed on 
the content validity. Good content validity increases motiva-
tion and reduces dissatisfaction among users (e.g. OS techni-
cians or medical specialists) and respondents (e.g. patients), 
and makes it more likely that other stakeholders (e.g. policy 
makers, health insurance companies) accept the results (26). 
These are all essential aspects when considering application of 
MOS. Apart from the opinion of experts, there is no method to 
analyse content validity. MOS is based on a literature search 
and all experts indicated that the most relevant aspects of use 
and usability of OS are included. We conclude that content 
validity of MOS can therefore be regarded as satisfactory.
All questions in MOS were formulated in a manner that 
was preferred by most experts. This is a strong point from a 
respondent-focused view, because it enhances clarity and the 
practical application of the questionnaire. On the other hand, 
it is also a limitation. The questions in MOS are formulated 
in different ways by using either a VAS or multiple choices 
with 2, 3, 4, or 5 response categories. Consequently, it is not 
possible to calculate an interpretable sum-score or to perform 
a factor-analysis on MOS. This means that the underlying con-
structs of the questionnaire cannot be determined. With MOS, 
it is therefore not possible to identify the relationships between 
the different aspects of usability or the relative importance of 
these aspects with regard to use. MOS can, however, be used to 
gain insight in patients’ opinions with regard to the measured 
aspects of use and usability separately.
A possible limitation of the reproducibility study is that 
MOSprefv and MOSpostfv were not completed by the same 
subjects. However, reproducibility was determined through a 
within-group design that is not affected by differences between 
the groups. Furthermore, both parts of MOSfv were completed 
by patients at appropriate timing (i.e. prior to receiving OS or 
after having used OS for 2–4 months). If the same patients had 
completed both parts, there would have been an interval of ap-
proximately 6 months between completing the pre and the post 
part. In that period, relevant changes in a patient’s health status 
may occur. Finally, there are no reasons to expect different re-
producibility scores between the groups, because there were no 
large differences in the patient characteristics of both groups and 
the methods of administration of the patients were the same.
With regard to the application of MOS, some remarks can 
be made. First, MOS was specifically designed for first-time 
users. The difference between first-time and experienced 
users is essential in the interpretation of outcomes of MOS. 
First-time users compare their (future) pair of OS with their 
normal shoes, whereas experienced users compare their new 
pair of OS with their previous pair(s) of OS and possibly with 
previous normal shoes. This different frame of reference may 
influence expectations and experiences of a user’s (future) pair 
of OS, and thereby influence the outcomes of MOS. There-
fore, when MOS is administered to a group of patients, the 
outcomes of first-time users and experienced users should be 
separated. Furthermore, it should be kept in mind that some 
questions may need to be added when MOS is administered 
to experienced users. For example, with regard to the number 
of pairs that have previously been worn. The second remark 
concerns the language of the questionnaire. MOS has been 
developed specifically for the Dutch situation. Cross-cultural 
adaptation of MOS to other countries will be a useful step to 
enhance research regarding use and usability of OS around 
the world. The Dutch version of MOS and its English version 
(unilaterally translated by the authors) are available from the 
corresponding author.
In conclusion, MOS is the first practical and reproducible 
questionnaire that can measure the most relevant aspects of 
use and usability of OS from a patient’s perspective, for a wide 
range of patient groups. MOS is short and easy to complete, 
and can be used for evaluation of a group of patients, as well 
as for assessment of an individual patient. 
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APPENDIx I. Combination of key words used in the literature search 
in Medline
#1 ((Orthopaedic or orthopedic or therapeutic or surgical or 
prescrib*) near1 (shoe* (MeSH) or foot* (MeSH))
#2 Patient satisfaction or usability or non-use
#3 Diabetes mellitus (MeSH)
#4 Rheumatic diseases (MeSH)
#5 Foot deformities (MeSH)
#6 Foot diseases (MeSH)
#7 PY > 1989
#8 #1 and #2
#9 #3 or #4 or #5 or #6
#10 #8 and #9 and #7
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